Epigenomics appeals recent FDA request for additional information
Epigenomics announced that after discussions with FDA in relation to its premarket approval application for the Company’s blood-based colorectal cancer screening test Epi proColon®, it is appealing the agency’s decision on additional data requirements. November 25, 2015